https://pharminent.com/astrazeneca-positions-rare-diseases-at-center-of-80-billion-ambition/ 2026-07-20T20:55:29Z Pharminent en AstraZeneca Positions Rare Diseases at Center of $80 Billion Ambition 2026-07-20T20:55:29Z Blog https://pharminent.com/samsung-biologics-acquires-swiss-cdmo-polypeptide-in-1-81bn-all-cash-deal/ 2026-07-20T20:33:05Z Pharminent en Samsung Biologics Acquires Swiss CDMO PolyPeptide in $1.81bn All-Cash Deal 2026-07-20T20:33:01Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-july-20-2026/ 2026-07-20T20:25:03Z Pharminent en Rare Disease & Gene Therapy Digest • July 20, 2026 2026-07-20T20:25:01Z Blog https://pharminent.com/week-in-review/week-in-review-intelligence-brief-july-18-2026/ 2026-07-20T17:53:28Z Pharminent en Week in Review • INTELLIGENCE BRIEF • July 18, 2026 2026-07-20T17:53:26Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-july-20-2026/ 2026-07-20T15:55:53Z Pharminent en Strategic News Watch • July 20, 2026 2026-07-20T15:55:51Z Blog https://pharminent.com/lundbeck-preps-for-key-bexicaserin-data-around-year-end/ 2026-07-20T20:52:14Z Pharminent en Lundbeck preps for key bexicaserin data around year-end 2026-07-20T12:59:54Z Blog